Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.44 |
| ▸ | WDR5 | P61964 | 3/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BRD1 | O95696 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29902299 | 0.85 | SMN1; SMN2 (0.64) | TRPV4SMN1; SMN2GLATSHRGAA | |
| SCHEMBL47015 | 0.85 | SMN1; SMN2 (0.64) | TRPV4SMN1; SMN2GLATSHRGAA | |
| SCHEMBL4573199 | 0.83 | SMN1; SMN2 (0.50) | TRPV4SMN1; SMN2GLATSHRGAA | |
| SCHEMBL16005133 | 0.81 | PKM (0.53) | TRPV4SMN1; SMN2GLATSHRGAA | |
| SCHEMBL31556387 | 0.81 | PKM (0.53) | TRPV4SMN1; SMN2GLATSHRGAA | |
| SCHEMBL17315165 | 0.81 | SMN1; SMN2 (0.47) | TRPV4SMN1; SMN2GLATSHRGAA | |
| SCHEMBL27601631 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2GLATSHRGAAACLY | |
| SCHEMBL18498692 | 0.81 | TRPV4 (0.44) | TRPV4SMN1; SMN2GLATSHRGAA | |
| SCHEMBL16469895 | 0.81 | TRPV4 (0.61) | TRPV4SMN1; SMN2GLATSHRGAA | |
| SCHEMBL31050364 | 0.80 | SMN1; SMN2 (0.46) | TRPV4SMN1; SMN2GLATSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111574414-A | Synthesis method of 4-bromo-2-methoxybenzenesulfonyl chloride | 上海毕得医药科技有限公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2026099404-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | QUBIT PHARMACEUTICALS (FR) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741375-A1 | SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | Qubit Pharmaceuticals (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025098417-A1 | SULFONAMIDE COMPOUND AND USE THEREOF | 再和医药科技（苏州）有限公司 | 2025-05-15 | — | — | WO | disclosed |
| CN-119176818-A | Sulfonamide compounds, pharmaceutical compositions and uses thereof | 北京康辰药业股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240308992-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Biopolar Youtang(Guangdong) Pharmaceutical Co., Ltd. (CN) | 2024-09-19 | — | — | US | disclosed |
| EP-4431508-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Biopolar Youtang (Guangdong) Pharmaceutical Co., Ltd. (CN) | 2024-09-18 | — | — | EP | disclosed |
| WO-2006010629-A1 | PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | WO | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0516257-B1 | Phenylbenzo[b]furans and -thiophenes, procedures for their preparation, and pharmaceutical compositions containing the same | SCHERING AG (DE) | 1998-08-05 | — | — | EP | disclosed |
| EP-0569193-B1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5470854-A | Antiestrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-28 | — | — | US | disclosed |
| EP-0569193-A1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
| WO-1992021669-A1 | 2-PHENYLBENZO[B]FURANS AND THIOPHENES, METHODS OF PREPARING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-10 | — | — | WO | disclosed |
| EP-0516257-A1 | Phenylbenzo[b]furans and -thiophenes, procedures for their preparation, and pharmaceutical compositions containing the same | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | TRPV4 1449/4885SMN1; SMN2 2026/4885GLA 1714/4885 |
| US-20240308992-A1 | DRAK2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | VRK2, MAPKAPK2, DAPK2 | TRPV4 3194/4885SMN1; SMN2 2775/4885GLA 2957/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | TRPV4 909/4885SMN1; SMN2 2992/4885GLA 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.